SPRY - NASDAQ

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%

HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$900.68M

EPS-1.7400

P/E Ratio-5.21

Earnings Date08/12/2026

spry

Change in Working Capital

Last Annual Value

-20.00M

3-Year CAGR

-16%

5-Year CAGR

-33%

10-Year CAGR

-47%

Adjust for Inflation

ARS Pharmaceuticals, Inc. Competitors Analysis of Change in Working Capital

SPRY · NASDAQ

Company	Change in Working Capital	CAGR 3Y	CAGR 5Y	CAGR 10Y
ARS Pharmaceuticals, Inc. NASDAQ:SPRY	-20.00M	N/A	N/A	N/A
Arbutus Biopharma Corporation NASDAQ:ABUS	-10.02M	N/A	N/A	N/A
Savara Inc. NASDAQ:SVRA	5.00M	7.1%	N/A	12.8%
Kura Oncology, Inc. NASDAQ:KURA	184.44M	186.8%	N/A	N/A
Palvella Therapeutics, Inc. NASDAQ:PVLA	3.82M	N/A	-34.0%	N/A
LENZ Therapeutics, Inc. NASDAQ:LENZ	3.25M	-29.8%	N/A	N/A
ProKidney Corp. NASDAQ:PROK	1.28M	-57.5%	-10.0%	N/A
Tyra Biosciences, Inc. NASDAQ:TYRA	-1.63M	N/A	N/A	N/A
Rezolute, Inc. NASDAQ:RZLT	47.00K	-64.2%	N/A	N/A

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $9.07

Related Guides

Blog Categories

Continue your SPRY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.